The Antibacterial Resistance Leadership Group: Progress Report and Work in Progress

The Antibacterial Resistance Leadership Group (ARLG), with funding from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, was created in June 2013. Its mission is to develop, prioritize, and implement a clinical research agenda that addresses the public...

Full description

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases 2017-03, Vol.64 (suppl_1), p.S3-S7
Main Authors: Chambers, Henry F. "Chip", Cross, Heather R., Evans, Scott R., Kreiswirth, Barry N., Fowler, Vance G.
Format: Article
Language:English
Subjects:
Anti-Bacterial Agents - pharmacology
Anti-Bacterial Agents - therapeutic use
Biomedical Research - organization & administration
Drug resistance
Drug Resistance, Bacterial
Funding
Humans
Infectious diseases
Leadership
Public health
Research Report
Supplement
Voluntary Health Agencies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The Antibacterial Resistance Leadership Group (ARLG), with funding from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, was created in June 2013. Its mission is to develop, prioritize, and implement a clinical research agenda that addresses the public health threat of antibacterial resistance. This article reports on the progress that the ARLG has made to date in fulfilling its mission. Since inception, the ARLG has received and reviewed > 70 study proposals, initiated > studies, executed >300 agreements, included data from >7000 subjects, published >45 manuscripts, and provided opportunities for 26 mentees. Despite this substantial progress, there remains significant work to be accomplished. This article also describes the considerable challenges that lie ahead.
ISSN:1058-4838
1537-6591
DOI:10.1093/cid/ciw824